IMD-3-2000 © 2008
Deschamps, Jean-Philippe ; Barnett Berg, Michèle
They were critical for EDAP to reach its objective of reaching United States FDA approval, an essential condition for the business's development in the world's biggest prostate cancer market. Within the previous years, EDAP had actually made considerable development in recording the interest from the urological medical neighborhood and enhancing the number of websites utilizing its innovation and of clients dealt with sufficiently. Market penetration for HIFU still dealt with particular concerns: Its status as a speculative therapy, unwillingness of urologists to embrace a brand-new innovation over surgical treatment, competitors from other innovations and treatment methods, conservative mindsets from the health repayment firms, and EDAP's significant resource restraints.
In the brief to medium term, the business required to envision innovative methods
to speed up the adoption of its innovation in Neighboring and european markets. In the longer term, EDAP had to identify the most preferable development course beyond its present prostate cancer activities. Knowing goals: To consider and analyze how a business gears their efforts to get a brand-new medical innovation accepted prior to it is a requirement of care.Subjects: Prostate cancer; Medical technology; HIFU; Alternative therapies; Standard of care; Medical device; Clinical trials; Research and Development; R&D
Settings: Worldwide; Medical device; Medical technology; 2007 revenues of € 22 million; 2000-2008
Related Case Solutions & Analyses:
Mall of America (A)
CSFBs China Unicom Incident
Mutual Funds
MBA 510 Financial Accounting Financial Analysis Project
Note on Financial Statement Analysis
Note on Management Control Systems in Health Care
Apogee Health Care
Sarvajal: Water for All
Hamilton’s Electronics Services, Inc.
Exotic Interest Rate Swaps: Snowballs in Portugal
